PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner

Clear cell renal cell carcinoma (ccRCC) is the most lethal form of kidney cancer and effective treatment regimens are yet to be established. Tyrosine kinase inhibitors (TKI) have widely been used as ccRCC therapeutics, but their efficacy is limited due to accompanying resistance mechanisms. Previous...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Minghua Cao, Karol Nawalaniec, Amrendra K. Ajay, Yueming Luo, Romana Moench, Yanfei Jin, Sheng Xiao, Li-Li Hsiao, Ana Maria Waaga-Gasser
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2022-05-01
coleção:	Translational Oncology
Assuntos:	Phosphodiesterase 4D cAMP Renal cell carcinoma Tyrosine kinase inhibitor MAPK/ERK pathway CRAF
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1936523322000390
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!